GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
FZD1 | 4038 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and IF staining and qRT-PCR | Up | 0.48 | 0.0042 | 25731617
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.1135 | 29702194
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.1135 | 25279705
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 1 | 29702194
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by FACs and Western Blotting | NA | 0.48 | 1 | 34949193
|
LINC01619 | 27409 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0011 | 32655789
|
PAX6 | 8620 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | Western Blotting and RT-PCR followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0021 | 31024010
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.6448 | 29702194
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.48 | 0.6448 | 25960639
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by IF staining and qRT-PCR | NA | 0.48 | 0.6448 | 25731617
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 34949193
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 25279705
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 28035349
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SP assay followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.6448 | 22862169
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.7582 | 29702194
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.7582 | 25279705
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | MACs | NA | 0.48 | 0.7582 | 24008862
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by FACs | NA | 0.48 | 0.7582 | 32676335
|
SUZ12 | 17101 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 25279705
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.0891 | 25960639
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.5461 | 25960639
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by FACs and qPCR | NA | 0.44 | 0.5461 | 25731617
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Western Blotting | NA | 0.44 | 0.5461 | 34949193
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qRT-PCR | NA | 0.44 | 0.5461 | 28035349
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.5695 | 25960639
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Western Blotting | NA | 0.44 | 0.5695 | 34949193
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | SFA followed by qRT-PCR | NA | 0.44 | 0.5695 | 25279705
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by qRT-PCR | NA | 0.44 | 0.5695 | 28035349
|
MYH9 | 7579 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0064 | 34635641
|
BACH1 | 935 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0011 | 34949193
|
FZD10 | 4039 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25731617
|
FZD2 | 4040 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25731617
|
LRP5 | 6697 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25731617
|
LRP6 | 6698 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25731617
|
WNT2 | 12780 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 25731617
|
WNT3A | 15983 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 25731617
|
WNT5A | 12784 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25731617
|
WNT7A | 12786 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25731617
|
WNT7B | 12787 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25731617
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SP assay followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.1739 | 22862169
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | ALDEFLUOR assay | NA | 0.12 | 0.684 | 32655789
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by ALDEFLUOR assay | NA | 0.12 | 0.684 | 22807978
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | Docetaxel | FACs followed by SFA and Tumorigenicity assay | NA | 0.12 | 0.211 | 25279705
|
CREBBP | 2348 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25731617
|
CSNK1A1 | 2451 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25731617
|
CTNNB1 | 2514 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0647 | 25731617
|
GSK3B | 4617 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25731617
|
LEF1 | 6551 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25731617
|
TCF7l2 | 11641 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | SPCA1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25731617
|